[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499681":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":39,"locations":44,"responsibleParty":145,"collaborators":25,"id":147,"slug":148,"hasResults":149,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":149,"sex":155,"minAge":156,"maxAge":25,"enrollmentInfo":157,"targetDuration":25,"studyType":160,"phases":161,"briefSummary":163,"conditions":164,"keywords":25,"overallStatus":47,"whyStopped":25,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Yale University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Beta-Blockers (BB) Therapy","EXPERIMENTAL","Participants randomized to this arm will be given a beta-blocker. Specific and appropriate drug selection from the class of beta blockers (i.e. type of BB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All BB will be administered orally (i.e. pills).",[13,14],"Other: Clinician Discretion","Drug: Beta blocker",{"label":16,"type":10,"description":17,"interventionNames":18},"Calcium Channel Blockers (CCB) Therapy","Participants randomized to this arm will be given a calcium channel blocker. Specific and appropriate drug selection from the class of calcium channel blockers (i.e. type of CCB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All CCB will be administered orally (i.e. pills).",[13,19],"Drug: Calcium channel blocker",[21,26,31],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Clinician Discretion","Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.",[9,16],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DRUG","Beta blocker","Selection of the specific BB and initial starting dose will be determined by the treating clinician.",[9],{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":25},"Calcium channel blocker","Selection of the specific CCB and initial starting dose will be determined by the treating clinician.",[16],[36],{"name":37,"affiliation":5,"role":38},"Michael Nanna, MD","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":25,"email":43},"CONTACT","(888) 683-0865","livebetter-trial@yale.edu",[45,59,69,79,89,98,105,111,121,135],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":25},"Yale School of Medicine","RECRUITING","New Haven","Connecticut","06520","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-72.92816,41.30815,{"lat":57,"lon":56},{"facility":60,"status":47,"city":61,"state":62,"zip":63,"country":51,"countryCode":52,"cosmosGeoPoint":64,"geoPoint":68,"contacts":25},"Wellstar Research Institute","Marietta","Georgia","30060",{"type":54,"coordinates":65},[66,67],-84.54993,33.9526,{"lat":67,"lon":66},{"facility":70,"status":47,"city":71,"state":72,"zip":73,"country":51,"countryCode":52,"cosmosGeoPoint":74,"geoPoint":78,"contacts":25},"Cook County Health","Chicago","Illinois","60612",{"type":54,"coordinates":75},[76,77],-87.65005,41.85003,{"lat":77,"lon":76},{"facility":80,"status":47,"city":81,"state":82,"zip":83,"country":51,"countryCode":52,"cosmosGeoPoint":84,"geoPoint":88,"contacts":25},"Brigham and Women's Hospital","Boston","Massachusetts","02115",{"type":54,"coordinates":85},[86,87],-71.05977,42.35843,{"lat":87,"lon":86},{"facility":90,"status":47,"city":91,"state":91,"zip":92,"country":51,"countryCode":52,"cosmosGeoPoint":93,"geoPoint":97,"contacts":25},"Mt. Sinai Health System","New York","10029",{"type":54,"coordinates":94},[95,96],-74.00597,40.71427,{"lat":96,"lon":95},{"facility":99,"status":100,"city":91,"state":91,"zip":101,"country":51,"countryCode":52,"cosmosGeoPoint":102,"geoPoint":104,"contacts":25},"NYC Health and Hospitals, Harlem Hospital","NOT_YET_RECRUITING","10037-1802",{"type":54,"coordinates":103},[95,96],{"lat":96,"lon":95},{"facility":106,"status":47,"city":91,"state":91,"zip":107,"country":51,"countryCode":52,"cosmosGeoPoint":108,"geoPoint":110,"contacts":25},"Nirvana Integrative Medicine","10469",{"type":54,"coordinates":109},[95,96],{"lat":96,"lon":95},{"facility":112,"status":47,"city":113,"state":114,"zip":115,"country":51,"countryCode":52,"cosmosGeoPoint":116,"geoPoint":120,"contacts":25},"Duke University, School of Medicine","Durham","North Carolina","27710",{"type":54,"coordinates":117},[118,119],-78.89862,35.99403,{"lat":119,"lon":118},{"facility":122,"status":100,"city":123,"state":124,"zip":125,"country":51,"countryCode":52,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":54,"coordinates":127},[128,129],-81.69541,41.4995,{"lat":129,"lon":128},[132],{"name":133,"role":41,"phone":134,"phoneExt":25,"email":25},"Abdulla Damluji, MD","216-630-3297",{"facility":136,"status":47,"city":137,"state":138,"zip":139,"country":51,"countryCode":52,"cosmosGeoPoint":140,"geoPoint":144,"contacts":25},"Inova Health Care Services","Fairfax","Virginia","22033",{"type":54,"coordinates":141},[142,143],-77.30637,38.84622,{"lat":143,"lon":142},{"type":146,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100499681","phase-4-livebetter-a-trial-comparing-medications-in-older-adults-with-stable-angina-and-multiple-chronic-conditions-100499681",false,"NCT05786417","LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions","A Trial Comparing the Effectiveness and Tolerability of Medications in Older Adults With Stable Angina and Multiple Chronic Conditions: LIVEBETTER","LIVEBETTER","Inclusion Criteria:\n\nOLDER ADULTS WITH SIHD AND MCC\n\n* Age ≥65 years\n* ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)\n* Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:\n\n  1. positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease\n  2. coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or\n\n     ≥50% stenosis of left main\n  3. Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤ 0.80 or iFR ≤0.89)\n\nCAREGIVERS\n\n* Age ≥ 18 years\n* Identified as caregiver of LIVEBETTER participant\n\nExclusion Criteria:\n\nOLDER ADULTS WITH SIHD AND MCC\n\n* Current taking (both) a beta-blocker AND a calcium channel blocker\\*\n* Contraindication to beta-blockers or calcium channel blockers including:\n\n  1. significant hypotension\n  2. high grade AV block\n  3. severe symptomatic bradycardia\n  4. severe obstructive lung disease\n* Documented intolerance to beta-blockers or calcium channel blockers\n* Probable or definite high-risk coronary artery disease including unrevascularized left main disease and\u002For unrevascularized multi-vessel disease including the proximal left anterior descending (LAD) artery with plans for immediate complete revascularization\n* Plans for complete revascularization within 2 weeks\n* Clear clinical indication for beta-blockers or calcium channel blockers that precludes dose adjustment or crossover:\n\n  1. Diagnosis of acute coronary syndrome (ACS) with reduced ejection fraction within past year\n  2. Heart failure with reduced ejection fraction (HFrEF) within past year\n* Actively participating in another clinical trial involving an investigational medication or device\n* Primary language other than English or Spanish\n* Inability to complete follow-up (e.g. life expectancy \\\u003C12 months, impaired decision-making determined by validated instrument)\n* Previously enrolled in LIVEBETTER\n* Refused informed consent\n\nCAREGIVERS\n\n* Professional caregiver (i.e. not a relative or close friend of the participant)\n* Primary language other than English or Spanish\n* Inability to complete follow-up\n* Previously enrolled in LIVEBETTER\n* Refused informed consent","ALL","65 Years",{"count":158,"type":159},741,"ESTIMATED","INTERVENTIONAL",[162],"PHASE4","To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).",[165,166],"Angina","Stable Ischemic Heart Disease","2026-04-06",{"date":169,"type":170},"2026-04-07","ACTUAL",{"date":172,"type":170},"2023-05-10",{"date":174,"type":159},"2027-05-30",{"name":5,"class":6},10]